Hyaluron

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hyaluron

What is Hyaluron? The Drug Identity and Composition

Property Description
Active ingredient Sodium Hyaluronate
Form Sterile solution or injectable gel
Pharmacological class Viscosupplementation Agent / Viscoelastic Substance
Common use Supporting joint function and surgical procedures
Origin Naturally occurring (Endogenous) polysaccharide derivative

What is Hyaluron and What is its Composition?

Hyaluron refers to medical preparations containing the active ingredient Sodium Hyaluronate, which is the sodium salt of Hyaluronic Acid (Hyaluronan). This substance is an endogenous compound, meaning it is a naturally occurring component found within the human body, particularly concentrated in the extracellular matrix of connective tissues.

Chemically, it is classified as a high-molecular-weight polysaccharide, belonging to the class of glycosaminoglycans. The key physical property of binding large volumes of water gives the molecule its role in maintaining tissue hydration and providing structural support. This biochemical role allows for therapeutic utility in replacing or supplementing reduced natural stores of Hyaluronan in the body.


What Type of Medicine is Sodium Hyaluronate?

Sodium Hyaluronate is categorized as a Viscosupplementation Agent or an Intra-Articular Agent when used for joint support, and as a Viscoelastic Substance when used during certain surgical procedures. These preparations function as medical aids that act as lubricants and provide temporary shock absorption in compromised joints.

The medicine helps restore the cushioning and lubricating properties required for smooth bodily movements. The drug is presented as a sterile solution or an injectable gel, administered via specific routes like intra-articular or intraocular injection. A differentiating factor for these products is the molecular weight and concentration of the Sodium Hyaluronate, which determines the specific use case.

What side effects are possible with Hyaluron?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse effects and safety characteristics of medical Hyaluronan preparations (Sodium Hyaluronate), based strictly on government regulatory documents (e.g., FDA Prescribing Information and EMA Summary of Product Characteristics).

Adverse Reactions and Frequencies

Adverse reactions are primarily localized to the administration site and are classified by frequency according to official regulatory standards:

Frequency Classification Examples of Associated Official Adverse Events
Very Common (ge 1/10) Joint Pain (Arthralgia), Joint Swelling/Inflammation
Common (ge 1/100 to < 1/10) Injection Site Pain, Headache, Nausea, Back Pain, Dizziness
Very Rare (< 1/10,000) Septic Arthritis, Anaphylactic/Anaphylactoid Reaction

Local reactions, such as injection site pain, swelling, and redness (erythema), are generally transient and typically resolve within a few days.


Serious Adverse Reactions and Systemic Classification

Serious Adverse Reactions officially documented, though rare, include Septic Arthritis (intra-articular infection) and Anaphylactic/Anaphylactoid Reactions (severe systemic allergic reactions). Reactions are grouped by System-Organ Class, affecting, for example, Musculoskeletal, Gastrointestinal, and Nervous System Disorders.

Safety Constraints and Special Populations

Official labeling mandates several restrictions on use:

  • Contraindications: The preparation is contraindicated in patients with a known hypersensitivity to Sodium Hyaluronate and must not be administered into areas with an active infection or skin disease at the injection site.
  • Special Populations: Safety and effectiveness have not been established for pregnant women, lactating mothers, and pediatric patients (under 21 years of age), according to regulatory documentation.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The official regulatory profile for Hyaluron (Sodium Hyaluronate), particularly in its injectable forms such as viscoelastic solutions, establishes the overdose risk as primarily local and related to administration, rather than systemic toxicity. This distinction is based on the substance's classification as an endogenous polysaccharide derivative.

Feature Regulatory Documentation Status
Documented Overdose Manifestations Primarily Localized Pain, Swelling, Joint Effusion, or Injection Site Discomfort at the administration site. Transient increases in intraocular pressure are noted for ophthalmic preparations following over-administration.
Physiological Systems Affected Restricted to the Local Musculoskeletal System (e.g., joints) and Ocular System. Systemic severe outcomes are generally not documented in regulatory overdose sections.
Required Emergency Response Symptomatic and Supportive Treatment is the mandated approach. Official labeling indicates that no specific antidote is known for systemic effects.

When Immediate Medical Help is Required

Regulatory guidance consistently emphasizes the need to seek immediate medical attention for any documented symptoms that are severe, persistent, or that rapidly worsen following the administration of the injectable gel or solution. Overdose is officially associated with the physical administration of an excessive volume of the product, resulting in a localized tissue reaction. For over-administration scenarios, medical monitoring or hospital observation may be required to ensure the complete resolution of the localized pain and swelling or to manage potential complications. Due to the localized nature of the risk, specific population-based overdose considerations (e.g., hepatic, renal, or pediatric groups) are typically not detailed in the official prescribing information. The requirement for urgent help is defined solely by the severity and progression of these localized manifestations.

Therapeutic Uses of Hyaluron

Hyaluronate is commonly used to help with managing symptoms in various therapeutic contexts. It is relevant for managing symptoms related to physical discomfort and is applied in contexts that involve symptomatic support for conditions involving inflammatory or irritative processes, relevant in a variety of symptomatic contexts.


Easing Symptomatic Discomfort

Hyaluronate is commonly used when short-term symptomatic assistance is needed during acute or disruptive episodes characterized by symptoms related to physical discomfort or inflammatory states. This application supports the patient during difficult episodes by easing distress during phases when symptoms become more noticeable. It is generally relevant for easing symptoms that interfere with daily functioning and create noticeable physiological strain.

The substance assists with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms in conditions where functional stability may be affected. It is relevant in conditions involving episodic or fluctuating manifestations, and is applied when symptoms cluster into patterns requiring supportive management.

Quick Fact: Supports Management of Symptoms that Interfere with Daily Functioning

Regulatory References

  1. NIH StatPearls Overview

Eligibility and Restrictions for Use

Eligibility for Sodium Hyaluronate Injections

Official regulatory documents define strict criteria for the use of injectable sodium hyaluronate preparations.

Population Status Regulatory Classification (Mandatory)
Absolute Contraindication Known hypersensitivity to any hyaluronate preparation. Infections or skin diseases at the injection site or joint.
Use with Caution/Restricted Patients with known allergies to avian products (for specific product formulations). Patients with inflammatory arthritis (e.g., rheumatoid arthritis). Patients with joint effusion (must be removed before injection).
Use Not Established Pediatric patients (typically le 21 years of age). Pregnant women and lactating/nursing mothers.

Eligibility is generally established only for adult patients. The product is not authorized for use in children or adolescents, as safety and effectiveness have not been demonstrated in these age groups. Similarly, use during pregnancy and lactation is not established by regulatory authorities. The primary contraindications are non-negotiable prohibitions for those with product allergy or an active infection in the area intended for treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes officially documented constraints and warnings regarding the use of Hyaluron (sodium hyaluronate/hyaluronan) with other medicinal products and substances, as mandated by regulatory documents.

Official Interaction Statements

Procedural Incompatibility: Official labeling states a do-not-combine rule for specific topical preparations. Disinfectants containing quaternary ammonium salts (such as benzalkonium chloride or cetylpyridinium) must not be used for skin preparation at the injection site. These agents can chemically cause the precipitation of hyaluronate.

Systemic Agents and Risk: Regulatory documents classify interactions with several systemic medicinal product categories as clinically important and potentially hazardous.

Agent Category Interaction Classification
Oral Anticoagulants Clinically Important, Potentially Hazardous
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) Clinically Important, Potentially Hazardous
Local Anesthetics Clinically Important, Potentially Hazardous
Furosemide Clinically Important, Potentially Hazardous

Binding Constraint: In specialized uses, such as ophthalmic procedures, Hyaluron is a polyanionic molecule that may bind to other concurrently administered ophthalmic solutions. This binding interaction has the potential to alter the other drug's effectiveness, toxicity, or pharmacokinetic profile. The overall interaction profile is structured to restrict local incompatibilities and flag systemic agents that may increase clinical risk.

Mechanism of Action

Sodium Hyaluronate (Hyaluronan) exerts its function through a precise bimodal mechanism, combining physical-mechanical action with biochemical-cellular modulation to influence the physiological environment of the target tissue.

Viscoelastic Supplementation and Mechanical Shielding

This domain describes the physical mechanism where the high-molecular-weight Hyaluronan physically supplements the synovial fluid, increasing its viscosity and elasticity. The molecule creates a durable boundary layer lubricant over the articular cartilage surface, which directly contributes to the physiological change of reducing friction and providing shock absorption against compressive forces during movement.

Chondrocyte and Synovial Cell Modulation

This second domain addresses the biochemical mechanism involving the chondrocytes and synoviocytes within the joint. Through interaction with cell surface receptors like CD44, Hyaluronan modulates the local signaling patterns, influencing the release of pro-inflammatory mediators and cartilage-degrading enzymes ( MMPs). This action is associated with maintenance of chondrocyte viability, altering the metabolic balance towards an anabolic state, resulting in a mechanism influencing cartilage integrity and articular homeostasis.

Dosage and Administration Information

How Hyaluron is Used (Official Administration Guidelines)

Hyaluronate preparations, used primarily for viscosupplementation, are administered following strict protocols outlined in standard prescribing guidelines. These instructions ensure standardized use and define the required administration conditions.


Administration Scope and Route

Category Instruction
Route of Administration Intra-articular injection (into the joint cavity). Certain forms are also approved for Intraocular injection in surgery. The injection must be delivered intra-articularly only; it must not be administered intravascularly or extra-articularly.
Dosing Schedule Administered as a pre-determined cycle of injections, typically ranging from one to five injections per course. Doses, such as 20 mg or 25 mg per knee, are product-specific.
Frequency For multi-injection products, injections are typically given once a week. Repeat courses, if required, should not be initiated at intervals less than six months.

Procedural and Population Requirements

Category Instruction
Special Procedures Strict aseptic technique is mandatory. Any joint effusion must be removed (aspirated) prior to injection. Disinfectants containing quaternary ammonium salts must not be used for skin preparation (to avoid precipitation).
Post-Injection Care Patients are advised to avoid strenuous or prolonged weight-bearing activities on the treated joint for approximately 48 hours following the injection.
Age-Group Rules No explicit dose adjustment is typically required for older adults. Safety and effectiveness have generally not been established for use in pediatric patients.

These official administration instructions define a precise treatment protocol, ensuring the medication is used according to established clinical protocols.

Recent Clinical Evidence

Research evidence / Overview of studies for Hyaluron

Evidence for Viscosupplementation in Compromised Joints

Research exploring how symptoms change over time in patients with joint discomfort was studied for Hyaluron. The research base includes Randomized Controlled Trials (RCTs), where Hyaluron was studied for outcomes related to physical discomfort in joints like the knee, hip, and shoulder. These trials are studied alongside numerous Systematic Reviews and Meta-Analyses that pool data from many individual studies and contribute to the broader evidence landscape.

Studies were conducted during periods of increased symptom activity and often included adults managing conditions marked by functional limitations. Findings from these reviews describe patterns observed in the studies related to outcomes related to physical discomfort during the short-term study period. A notable magnitude of symptomatic improvement was observed in the placebo control groups across many injection studies. This factor was observed in the evidence describing how symptoms are measured in these studies.

How Trials Measured Symptomatic Change

To assess its effects, researchers explored changes using standardized methods. Studies mainly focus on outcomes reflecting daily functioning or activity level, using tools like the WOMAC index. Trials used patient-reported outcomes describing perceived discomfort and outcomes monitoring physiological strain or stress and studies monitored whether individuals met predefined response criteria.


Evidence for Use as a Viscoelastic Support in Other Contexts

Hyaluron was evaluated in other contexts, aligning with its classification as a Viscoelastic Substance. Research has explored whether it was associated with outcomes reflecting daily functioning in non-articular tissues. For ocular issues, studies focused on outcomes linked to inflammatory or irritative states and studies monitored outcomes related to tear film stability. Research provides insight into short-term changes in these areas.


Key Areas of Uncertainty and Study Gaps

One significant gap is the inconsistency of findings across the entire body of research. This evidence quality varies across studies, contributing to controversy in major clinical guidelines regarding the interpretation of the research. The evidence was studied for the specific populations and precise product characteristics and concentrations studied, and long-term effects are not fully established.

Key Studies & References

  1. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis
  2. Hyaluronic acid in the treatment of dry eye disease (Systematic Review)

Frequently Asked Questions (FAQ)

Common questions about Hyaluron (FAQ)


Q: How quickly can someone expect to see an effect from Hyaluron?

Clinical studies have investigated the time course of change in patient-reported outcomes. According to some official product information, improvement may not be observed until after a specific number of injections in a multi-injection course. Individual response to the product can vary.


Q: How long does the effect of Hyaluron usually last?

Clinical trials have monitored patient outcomes for periods up to six months following the final administration. Official prescribing instructions state that a new treatment course, if required, should not be initiated at intervals less than six months.


Q: Is Hyaluron a prescription drug or can it be purchased over the counter?

Medical preparations of Hyaluron for intra-articular and intraocular use are specialized products. The administration route, which requires a trained healthcare professional, is consistent with products that are not sold over the counter.


Q: What are some documented but rare side effects of Hyaluron?

The official regulatory labeling documents rare but serious adverse events. These include joint infection, also known as septic arthritis, and severe allergic reactions, referred to as anaphylactic or anaphylactoid reactions. These localized events are generally described in regulatory documents as being transient.


Q: What class of drug does Hyaluron belong to?

Hyaluron (Sodium Hyaluronate) is officially classified as a Viscosupplementation Agent when it is used to support joint function. The World Health Organization (WHO) also categorizes it as a drug used for musculo-skeletal disorders.


Q: Is Hyaluron the same as hyaluronic acid that's in cosmetics?

While the active substance is chemically related to the hyaluronic acid used in cosmetic products, the medical product must meet specific, very high purity requirements for factors like protein impurities and endotoxins, as it is designed for internal administration.


Q: Does Hyaluron cause weight gain?

Weight gain is not listed as a documented adverse reaction in the official regulatory prescribing information for intra-articular Hyaluron preparations.


Q: Can people with diabetes use Hyaluron?

Diabetes is not listed as a contraindication (a reason to prohibit use) for Hyaluron injections in official regulatory documents. The decision for use with underlying conditions is addressed through standard patient assessment.


Q: Is Hyaluron safe to use if I have an existing heart condition?

Official regulatory prescribing information does not list general heart conditions as a contraindication or a specific warning. The regulatory documents do, however, flag potential interactions with certain medications, such as anticoagulants and NSAIDs, which may be prescribed to patients with heart conditions.


Q: What is the difference between Hyaluron and other joint-support substances I see advertised?

Hyaluron, in its medical form, is specifically regulated as a Viscosupplementation Agent administered via injection. It is administered to provide viscosupplementation. This regulatory classification and route of administration differ from orally administered supplements, which follow separate regulatory pathways.


Q: Are there different forms of Hyaluron available (e.g., injections, oral, topical)?

The medical product is regulated for use as a sterile solution or injectable gel for specific routes, such as injection into a joint or the eye. Official regulatory documentation focuses exclusively on these injectable forms (solution or injectable gel) for administration.


Q: What should I do if I suspect an allergic reaction to Hyaluron?

Official information for all prescription products states that signs of a severe allergic reaction, such as difficulty breathing, hives, or swelling of the face, lips, or tongue, warrant immediate emergency evaluation.


Q: Is it possible to be resistant or non-responsive to the effects of Hyaluron?

Evidence from clinical trials indicates that the observed symptomatic improvement included a notable level of improvement in placebo control groups. This information, along with variability across study findings, indicates that individual patient response to treatment can differ.


Q: Is Hyaluron an anti-inflammatory drug?

Hyaluron is formally classified as a Viscosupplementation Agent. Its mechanism of action includes influencing the release of pro-inflammatory mediators, but it is not classified as a traditional Non-Steroidal Anti-Inflammatory Drug (NSAID) or a traditional anti-inflammatory medicine.


Q: Can Hyaluron affect blood pressure?

Official product labeling for certain preparations lists an increase in blood pressure as an adverse event reported in a small percentage of patients during clinical trials.


Q: If Hyaluron is naturally in the body, why is it needed as a medicine?

Hyaluron is administered as a medicine because the natural concentration and quality of the substance in compromised areas, such as joint fluid, may be diminished. Supplementing the natural stores helps restore the substance’s natural role in providing cushioning and lubrication.


Q: Do older people use Hyaluron differently than younger adults?

Official regulatory documents specifically state that no explicit dose adjustment is typically required for older adults.


Q: Can Hyaluron make me sensitive to the sun?

Increased sensitivity to the sun (photosensitivity) is not listed as an official or common adverse reaction in the regulatory prescribing information for Hyaluron preparations.


Q: Is there a maximum time Hyaluron should be used for?

Official prescribing instructions define a course of treatment as a finite, pre-determined cycle of injections. While repeat courses are allowed after a specific interval, there is no official lifetime maximum duration specified in regulatory labeling.


Q: What are the common signs that Hyaluron is starting to work?

The effectiveness of the product in clinical trials is measured using patient-reported outcomes that reflect changes in physical discomfort and the ability to perform daily functions. These changes in mobility and comfort are the typical signs patients might observe.


Q: Does Hyaluron contain any preservatives or inactive ingredients that might cause a reaction?

Medical preparations of Hyaluron contain the active ingredient Sodium Hyaluronate along with inactive ingredients, or excipients, such as salts or buffering agents, which vary by product brand. A known hypersensitivity to any component listed in the official product information is a contraindication to use.

How should Hyaluron be stored and disposed of?

How to Store and Dispose of Hyaluron (Sodium Hyaluronate)

The official storage and disposal requirements for Hyaluron injections are strictly defined by regulatory labeling to ensure product stability and sterility. These mandates require storing the product under controlled conditions:

Official Storage Rules

Condition Requirement
Temperature Store below 25 C or 30 C (ambient temperature).
Freezing DO NOT FREEZE under any circumstances.
Packaging Keep in the original, undamaged package and protect from light until use.
Stability Contents are for single use only; use immediately upon opening and discard any unused portion.

Disposal Instructions

Used syringes and needles must be immediately placed in a designated sharps disposal container. Do not dispose of the product or syringe in household trash or sinks, and follow local regulations for medical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hyaluron found in:

A-Z Index: